FCER1A rs2494262: Genetic Influences on Total Serum IgE
The rs2494262 single nucleotide polymorphism is an upstream regulatory variant located in the FCER1A gene on chromosome 1. This gene encodes the alpha subunit of the high-affinity receptor for immunoglobulin E (FcεRI), an essential molecular component of allergic signaling. Genome-wide and candidate-gene studies link this variant to modest variations in circulating total IgE concentrations and allergic susceptibility in diverse populations.
What each genotype means
| Genotype | What the research suggests | Reading |
|---|---|---|
| AA | Homozygous for the A allele. In multiple association studies, this genotype represents the baseline or higher-frequency allele configuration typically associated with standard baseline expression of FCER1A and reference circulating IgE ranges. | Informational |
| AC | Heterozygous carrying one copy of each allele. Individuals with this genotype typically exhibit intermediate regulatory activity between the two homozygous states, with modest statistical shifts in total circulating IgE depending on background ancestry. | Informational |
| CC | Homozygous for the minor C allele. Research studies have linked this genotype to statistical differences in FCER1A promoter activity and circulating IgE levels, though absolute clinical manifestations remain strongly dependent on environmental allergen exposures. | Higher attention |
Genomic Location and Variant Characteristics
The single nucleotide polymorphism rs2494262 is located on human chromosome 1q23.2 within the regulatory promoter region of the FCER1A gene (historically referenced in literature as the -18483A>C locus). At this specific genomic position, the primary alleles observed in human populations are adenine (A) and cytosine (C). Because it resides upstream of the protein-coding exons, rs2494262 does not alter the primary amino acid sequence of the resulting protein. Instead, it functions as a regulatory variant that can influence transcription factor binding, promoter activity, and subsequent expression levels of the high-affinity IgE receptor alpha subunit. In several populations, rs2494262 exists in varying degrees of linkage disequilibrium with other well-studied regulatory polymorphisms in the FCER1A promoter region, such as rs2251746 and rs2427837, which also participate in modulating receptor density on the surface of circulating immune cells.
Biological Function of the FCER1A Gene
The FCER1A gene encodes the alpha subunit of Fc epsilon RI (FcεRI), the high-affinity receptor for immunoglobulin E. This multi-subunit receptor is abundantly expressed on the surface of mast cells, basophils, eosinophils, and certain antigen-presenting dendritic cells. The alpha subunit forms the extracellular binding domain that directly contacts circulating IgE antibodies with nanomolar affinity. When multivalent environmental allergens cross-link IgE molecules bound to FcεRI, a rapid intracellular signaling cascade triggers the release of preformed mediators such as histamine, leukotrienes, and inflammatory cytokines. These chemicals produce the classic physiological signs of allergic reactions, including tissue edema, smooth muscle contraction, and mucous hypersecretion. Variations in FCER1A expression alter receptor density on effector cells, which can influence receptor stabilization, baseline cellular reactivity, and the clearance or biological titration of circulating serum IgE.
Research Associations with Serum IgE and Allergy Traits
Multiple genetic association studies have investigated rs2494262 in the context of atopy, allergic rhinitis, and baseline serum IgE measurements. Published evidence demonstrates that the variant is moderately associated with differences in total serum IgE concentrations, particularly in individuals with an atopic background. However, the scientific evidence also underscores noticeable ancestral and phenotypic divergence. For instance, while European cohorts frequently show statistically significant correlations between FCER1A locus variants and circulating IgE, studies conducted in Han Chinese populations have reported no statistically significant standalone association between rs2494262 and susceptibility to allergic rhinitis or baseline IgE. These findings suggest that the clinical impact of rs2494262 is polygenic and context-dependent, heavily modulated by gene-environment exposures such as early-life allergen exposure, air quality, and co-inherited immune response loci.
Population Frequency and Ancestral Distribution
Allele frequencies for rs2494262 vary substantially across global populations. In European populations, the minor allele frequency typically ranges between 0.30 and 0.40, resulting in a balanced distribution where heterozygous genotypes are widely observed alongside homozygous forms. By contrast, allele frequencies differ in East Asian, African, and Hispanic ancestral cohorts, which contributes to the mixed replicability seen across regional studies. Because baseline immune phenotypes and total serum IgE distributions naturally differ across continental ancestries due to evolutionary pathogen pressure and parasitic exposures, the phenotypic penetrance of regulatory FCER1A variants must be evaluated within specific demographic and ecological contexts rather than generalized globally.
Interpreting Genetic Results in Clinical Context
Knowledge of your rs2494262 genotype provides educational insight into baseline immune biology, but it cannot be used to diagnose allergic conditions, atopic dermatitis, or allergic rhinitis. Total serum IgE is a complex trait governed by hundreds of genomic loci, lifestyle variables, and environmental factors like allergen presence, smoking exposure, and infections. An individual carrying alleles associated with higher baseline IgE may never develop symptomatic allergies, while someone with low-risk genotypes can still experience severe allergic reactions. Genotyping results should never replace clinical evaluation, skin prick testing, or allergen-specific IgE blood panels. Furthermore, if you are being evaluated for biologic therapies targeting the IgE pathway (such as omalizumab), treatment decisions and dosing must always be guided by qualified healthcare providers and standardized clinical laboratory protocols.
How common is this variant?
The minor allele frequency for rs2494262 is approximately 0.30 to 0.40 in European populations, with significant variation in allele distributions reported across East Asian and African cohorts.
Frequently asked questions
Does having the rs2494262 variant mean I will definitely have allergies?
No, carrying a specific genotype at rs2494262 does not cause allergies on its own. Allergic conditions are complex traits influenced by many different genes alongside environmental triggers like pollen, pet dander, and diet. The variant only contributes a modest statistical difference to your baseline immune receptor regulation.
What is the difference between total IgE and specific IgE?
Total IgE measures the overall quantity of immunoglobulin E antibodies circulating in your bloodstream, which can be elevated due to genetics, allergies, smoking, or parasitic infections. Specific IgE tests, by contrast, measure antibodies directed against a precise allergen, such as peanut protein or birch pollen. The rs2494262 variant is studied primarily in connection with total circulating IgE levels.
Why do different scientific studies report conflicting results for rs2494262?
Genetic association results often vary due to ancestral differences, study sample sizes, and diverse environmental exposures. For example, while European studies have identified correlations with total IgE, studies in Han Chinese populations found no independent link to allergic rhinitis. These differences highlight how genetic effects can be modified by population-specific genetic backgrounds and environmental conditions.
Can this genetic test determine if I should take asthma medications like omalizumab?
No, consumer or research genetic testing for rs2494262 cannot determine your eligibility or dosing for anti-IgE biologic medications. Clinical prescription and dosing of targeted biologics depend on standardized clinical diagnostic criteria, symptom severity, and validated laboratory tests performed by a specialist. Always consult your physician or pharmacist regarding medication choices.
Sources & further reading
Educational information only, last refreshed 9/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2494262?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29